A randomized, 5‐arm dose finding study with a mite allergoid <scp>SCIT</scp> in allergic rhinoconjunctivitis patients

Abstract

In this mite allergoid SCIT dose finding study in HDM-induced ARC, concentrations of ≥20 000 AUeq/ml showed both immunological effects and clinical efficacy in the TNPT compared with placebo. The risk-benefit ratio favours 20 000 AUeq/ml and 50 000 AUeq/ml strengths for further clinical development.